Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cancer Aggressiveness Linked to Lack of COMMD1 Protein Activity

By LabMedica International staff writers
Posted on 14 Jun 2010
Cancer researchers have linked low levels of the COMMD1 (copper metabolism (Murr1) domain containing 1) protein to increased cancer aggressiveness and tendency to metastasize.

COMMD1 has been shown to inhibit both NF-kappaB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) and HIF (hypoxia inducible factor) mediated gene expression. More...
NF-kappaB and HIF are transcription factors that have been shown to play a role in promoting tumor growth, survival, and invasion.

In the current study, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied the role of COMMD1 expression in human cancers. They reported in the June 2010 issue of the Journal of Clinical Investigation that analysis of COMMD1 levels in 63 patients with endometrial cancer showed that those whose tumors had the lowest levels of COMMD1 had the worst clinical outcomes. Experiments in animals revealed that direct repression of the COMMD1 gene in human cell lines led to increased tumor invasion in a chick xenograft model, while increased COMMD1 gene expression in mouse melanoma cells led to decreased lung metastasis in a mouse model.

Decreased COMMD1 gene expression also correlated with increased expression of genes known to promote cancer cell invasiveness, including direct targets of HIF. At the molecular level the investigators found that COMMD1 inhibited HIF-mediated gene expression by binding directly to the amino terminus of HIF-1-alpha, preventing its dimerization with HIF-1-beta and subsequent DNA binding and transcriptional activation.

"This is the first study that clearly links COMMD1 to human disease and substantiates what we would have expected based on the prior work we have done on this protein,” said senior author Dr. Ezra Burstein, assistant professor of internal medicine and molecular biology at the University of Texas Southwestern Medical Center. "COMMD1 is yet another player in the very important and complicated cancer invasion process.”

"Further down the line we could create a drug that would bring COMMD1 protein levels back to normal, or even above normal, in the tumor to hopefully affect cancer cell invasion,” said Dr. Ezra Burstein. "If the cancer cells have already started invading other organs, maybe further invasion would be halted or even regressed.”

Related Links:

University of Texas Southwestern Medical Center




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.